Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

158.86
+2.621.68%
Post-market: 160.001.14+0.72%19:41 EDT
Volume:1.18M
Turnover:187.89M
Market Cap:303.10B
PE:24.02
High:159.72
Open:156.17
Low:156.10
Close:156.24
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:0.73
T/O Rate:0.06%
Dividend:4.67
Dividend Rate:2.94%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:7.30
PE(LYR):22.22

Loading ...

Novartis (NVS) Stock Rises on $2B Excellergy Acquisition to Expand Allergy Portfolio

TIPRANKS
·
Mar 27

Novartis to Acquire US Biotech Firm Excellergy in Deal Worth Up to $2 Billion

Deep News
·
Mar 27

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

Dow Jones
·
Mar 27

Novartis Acquires Excellergy for $2 Billion to Strengthen Food Allergy and Immune Disorder Portfolio

Stock News
·
Mar 27

Novartis to Acquire Excellergy For Up to $2 Billion

MT Newswires Live
·
Mar 27

Novartis Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 27

Morgan Stanley Sticks to Its Buy Rating for Novartis (NVS)

TIPRANKS
·
Mar 26

Novartis Ag : Morgan Stanley Raises Target Price to $170 From $143

THOMSON REUTERS
·
Mar 26

Novartis's Share Strength Raises Bar for Drug Pipeline -- Market Talk

Dow Jones
·
Mar 23

Novartis price target raised to $178 from $163 at BofA

TIPRANKS
·
Mar 23

Novartis CEO Highlights AI's Growing Role in Amplifying Healthcare Innovation

Deep News
·
Mar 23

Novartis to Acquire Synnovation Therapeutics Breast Cancer Drug Assets for Up to $3 Billion

Stock News
·
Mar 20

Novartis to acquire Pikavation Therapeutics from Synnovation Therapeutics

TIPRANKS
·
Mar 20

Dow Jones Top Company Headlines at 5 AM ET: Super Micro Computer Employees Arrested for Alleged Sales to China | Unilever ...

Dow Jones
·
Mar 20

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion -- Update

Dow Jones
·
Mar 20

Novartis (NVS) Receives a New Rating from Bernstein

TIPRANKS
·
Mar 20

Novartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences

Dow Jones
·
Mar 17

Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients

Benzinga
·
Mar 16

Novartis receives FDA approval for Cosentyx for patients aged 12 and older

TIPRANKS
·
Mar 14

Novartis AG Stock (NVS) Moved Down by 3.16% on Mar 11: Drivers Behind the Movement

TradingKey
·
Mar 11